Q1 Earnings Estimate for TG Therapeutics Issued By B. Riley

TG Therapeutics, Inc. (NASDAQ:TGTX) – Investment analysts at B. Riley issued their Q1 2025 EPS estimates for TG Therapeutics in a research note issued on Tuesday, March 4th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of $0.21 per share for the quarter. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics’ FY2026 earnings at $1.73 EPS.

Several other brokerages have also issued reports on TGTX. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. upped their price objective on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Trading Down 1.4 %

TG Therapeutics stock opened at $35.11 on Thursday. The business has a 50-day simple moving average of $30.86 and a two-hundred day simple moving average of $28.33. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $36.94. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market cap of $5.47 billion, a P/E ratio of -351.06 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, topping the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million.

Insider Activity

In related news, CFO Sean A. Power sold 10,021 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the sale, the chief financial officer now owns 660,611 shares in the company, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Vermillion Wealth Management Inc. bought a new stake in shares of TG Therapeutics during the fourth quarter valued at approximately $30,000. Quadrant Capital Group LLC increased its holdings in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 975 shares during the last quarter. Blue Trust Inc. grew its position in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of TG Therapeutics by 512.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock worth $60,000 after purchasing an additional 1,594 shares during the last quarter. Finally, Jones Financial Companies Lllp lifted its position in shares of TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 1,737 shares in the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.